Therapy with losartan compared to irbesartan was performed in a Chinese sample of hypertensive patients with elevated serum uric acid (SUA) levels. After 1 week of screening and a 2 week single-blinded placebo baseline period, patients were treated for 4 weeks with losartan 50 mg or irbesartan 150 mg. After 4 weeks, patients with SiDBPo90 mmHg and SiSBPo140 mmHg continued the same dose regimen for another 4 weeks. If blood pressure was not controlled after 4 weeks of treatment, the dose of either regimen was doubled to losartan 100 mg and irbesartan 300 mg. There were 351 patients randomized (176 to losartan and 175 to irbesartan), and of these, 325 patients completed the study (162 in the losartan group and 163 in the irbesartan group). At baseline, the median SUA level in the losartan group was 422 and 420 lmol/l in the irbesartan group. At 8 weeks of therapy, SUA decreased by 63 lmol/l in the losartan group compared to 12 lmol/l in the irbesartan group (Po0.0001). Blood pressure declined comparably in both groups from 151/92 mmHg at baseline to 137/83 and 135/83 (losartan and irbesartan, respectively, NS). No severe AEs were found for either treatment group. Therapy with losartan decreased SUA levels significantly more than irbesartan in Chinese patients with hypertension and elevated SUA levels, demonstrating the unique uricosuric effect of this ARB in this ethnic group.
Introduction
Elevated serum uric acid (SUA) is closely associated with several painful conditions, such as gout, kidney stones, vascular disease, renal disease, and cardiovascular events. 1 Interestingly, hypertension is present in 30% of all patients with elevated levels of SUA, or hyperuricaemia. 2 Elevated SUA is present in 25% of untreated hypertensive subjects, in 50% of subjects taking diuretics, and in 475% of subjects with malignant hypertension. 1 In patients at risk for hypertension, higher levels of SUA may be due to the decrease in renal blood flow that accompanies the hypertensive state. 1 In addition, diet, genetics or other influences are also important modulators of SUA levels. 3 Baseline SUA was significantly associated with an increased rate of the composite outcome in the LIFE study of cardiovascular death, fatal or nonfatal myocardial infarction, and fatal or nonfatal stroke (Po0.0001). 4 Other studies found that SUA is not an independent risk factor for cardiovascular disease or is even considered to be benign, except when associated with gout and kidney stones. 1 Gout is an acute, often recurrent arthritis mediated by the crystallization of uric acid within the joints and typically associated with elevated levels of SUA. 3 In one study, 72% of men with gout reported hyperuricaemia. 5 On the other hand, there have been several studies that clearly indicated that increased serum urate might be an independent risk factor for hypertensionassociated morbidity and mortality. 1, 6, 7 While a specific relationship continues to be debated, there is considerable interest in the potential importance of SUA in patients with hypertension and how to best treat them.
Losartan, an angiotensin II receptor antagonist, is an effective antihypertensive drug that also has a uricosuric effect due to its molecular disposition (or physical property). 2 The aims of this study were (1) to compare the effects of losartan and irbesartan on the change in uric acid levels in Chinese patients with mild to moderate essential hypertension and high levels of SUA; (2) to evaluate the antihypertensive efficacy of losartan and irbesartan in patients with mild to moderate essential hypertension and high levels of SUA; and (3) to determine the effects of losartan and irbesartan on lipid and glucose levels in patients with mild to moderate essential hypertension and high levels of uric acid.
Methods
Men and women enrolled in this study were aged X18 years old, with grade one to two essential hypertension (WHO, 1999 criteria), and hyperuricaemia (serum urate concentration X406 mmol/l in men; X310 mmol/l in women, Chinese criteria). 8 Patients with any of the following were excluded from the study: secondary hypertension; history of gout or renal lithiasis within the last 2 years; history of congestive heart failure; cerebrovascular accident, transient ischaemic attack, unstable angina pectoris or myocardial infarction within the last 3 months; clinically important cardiac arrhythmia; clinically significant hepatic or renal impairment (serum creatinine X176.8 mmol/l); concomitant therapy that might affect blood pressure, SUA, or urine volume; pregnancy or lactation; current drugs or alcohol abuse; history of neurologic or mental disorders; uncontrolled diabetes mellitus (fasting blood glucose 411 mmol/l); investigator apprehension about patient compliance with study protocol. The institutional Review Board of the Fu Wai Hospital approved this study and all subjects gave written informed consent.
Study design
This was a multicentre (20 clinical institutions), randomized, double-blind, and parallel clinical trial to compare the effects on SUA levels and the antihypertensive efficacy of losartan and irbesartan in a Chinese patient sample with mild to moderate essential hypertension and elevated SUA. The duration of the study was 11 weeks, which included 1 week of screening ( Figure 1 ). After 2 weeks of placebo, patients with 'trough' (obtained 22-26 h after morning drug administration) SiDBP between 90 and 109 mmHg, or SiSBP between 140 and 179 mmHg, and SUA X406 mmol/l in men and X310 mmol/l in women were randomized 1:1 to receive once daily therapy of either losartan (50 mg) or irbesartan (150 mg) orally for the first 4 weeks with the use of a computer-generated code. After 4 weeks of treatment, patients whose SiDBP o90 mmHg and SiSBP o140 mmHg continued the same dose regimen for another 4 weeks. If the blood pressure was not controlled (SiDBP X90 mmHg, or SiSBP X140 mmHg) after 4 weeks of treatment, the dose of either regimen was doubled to losartan (100 mg) or irbesartan (300 mg) for the following 4 weeks.
In this study, patients were instructed to follow a purine-restricted diet (o75 mg/day of purines). During the day preceding, as well as, on the day of blood sample collection, patients recorded their food and beverage intake in a diary card.
Clinical measurements and laboratory tests
SiDBP and SiSBP were measured at each clinic visit by conventional mercury sphygmomanometry and heart rate was obtained by palpation. The blood pressure measurement at 'trough' was taken at 24 h (range 22-26 h) after the last morning dose, that is, between 0800 and 1000. Fasting blood samples from all patients at screening were analysed for serum urate, serum glucose, total cholesterol, triglycerides, and high-density lipoprotein, serum potassium and creatinine. Laboratory tests were performed at screening, end of run-in, and at the end of active treatment of 8 weeks.
Data analysis
The analysis of the primary and continuous secondary parameters was performed by paired or unpaired Student's t-tests (SPSS). Data found to be nonnormally distributed were checked for statistical significance by the Wilcoxon's test (SPSS). Medians and percentiles are displayed for non-normally distributed data and other variables as mean7s.d. The primary end point was a comparison between the two treatment groups of the change in SUA from baseline to 8 weeks.
Results
There were 600 patients screened, of whom 351 patients were randomized (176 to losartan and 175 to irbesartan) ( Figure 2 ). Of these, 325 eligible patients completed the study (162 with losartan and 163 with irbesartan). There were nine patients who did not complete the trial after randomization because of poor compliance. The other patients were Effects of losartan and irbesartan A Dang et al dropped from the study because they did not follow the protocol strictly. As shown in Table 1 , both treatment groups were well matched for baseline clinical characteristics and demographics. Men comprised 58% of the losartan group and 57.7% of the irbesartan group, and no significant differences were found in any of the baseline characteristics between losartan and irbesartan, including age, weight, BMI, blood pressure, or SUA levels.
SUA levels
As shown in Figure 3 , losartan 50 mg once daily produced a significant decrease in SUA. The decreased SUA levels in the losartan group dropped from a median of 422 mmol/l at baseline to 367 mmol/ l at week 4 (Po0.0001), and losartan 50 or 100 mg once daily decreased SUA levels further to 359 mmol/l at week 8 (Po0.0001, by comparison to baseline). The decreased SUA levels in the irbesartan group dropped from a median of 420 mmol/l at baseline to 411 mmol/l at week 4 and to 408 mmol/l at week 8 (NS at both time points). For the primary end-point at 8 weeks, the change in median SUA levels was 63 mmol/l for the losartan group and 12 mmol/l for the irbesartan group (Po0.0001). The response of SUA to treatment was similar for men and women.
Antihypertensive efficacy Figure 4 demonstrates the blood pressure response to treatment. Both losartan and irbesartan treatments caused a significant decrease in blood pressure and 
Discussion
This was the first time to evaluate the effects of two AT 1 receptor antagonists on SUA in hypertensive patients with hyperuricaemia in Chinese population, which is the largest sample study in this field so far. The primary objective of this study was to compare the effects of losartan and irbesartan on uric acid levels in a Chinese patient sample with mild to moderate essential hypertension and elevated levels of SUA. Also, we evaluated the antihypertensive efficacy of losartan and irbesartan and determined the treatment effects on lipid and glucose levels in these patients. Losartan was first reported to decrease SUA in a dose-dependent manner with single doses ranging from 25-200 mg. 9 Previously, Sweet et al. 10 demonstrated that the uricosuric effect of losartan was due to the parent compound and not to the metabolite EXP-3174. 10 Thus far, losartan is the only angiotensin receptor blocker with uricosuric properties, and this study extends those findings in the Asian population.
In the LIFE study, losartan was shown to decrease the elevated levels of uric acid that hypertensives experience. Losartan attenuated the increase in SUA by comparison to the atenolol-treated group over the entire duration of the study of 4.8 years (17.0769.8 vs 44.4772.5 mmol/l; Po0.0001). In LIFE, baseline SUA was significantly associated with increased cardiovascular risk (HR, 1.024; 95% CI: 1.017-1.032, per 10 mmol/l increase). 1 In a secondary analysis of the LIFE study, it was shown that 29% of the reduction in the composite outcome measure (cardiovascular death, MI and stroke) in the losartan group could be explained by the difference in SUA over the course of the study (P ¼ 0.004), 4 though this Graph depicting the change in blood pressure for both the losartan and irbesartan treatment. There were no significant differences in the decline in blood pressure between treatment groups which was significant in both groups at all time periods (Po0.0001). Dotted reference lines are shown at 140 and 90 mmHg. Po0.05 between baseline and week 8. No significant differences were found in other parameters between the two treatment groups at week 8 (P40.05).
Effects of losartan and irbesartan
A Dang et al sample included few Asians. These results suggest that the unique uricosuric quality of losartan may be an added benefit of this particular angiotensin receptor blocker. Previously, it was shown that losartan induced a significant decrease in SUA levels in patients with hypertension, elevated levels of SUA, and gout, and that effect was not shared by irbesartan. 2 They found that increasing the dose of losartan from 50 mg once daily to twice a day did not further reduce SUA levels. In a similar study of Asian men with gout and hypertriglyceridaemia or hypertension, the addition of losartan to benzbromarone (Po0.05) or to allopurinol (Po0.01) caused a significant decrease in SUA. 11 Those results demonstrated an additive uric acid-lowering effect of fenofibrate and/or losartan in hypertriglyceridaemic and/or hypertensive patients with gout. In a small sample of Japanese men, losartan induced a slight time-dependent decrease in the SUA concentration from 5.970.9 to 5.271.0 mg/dl, while the comparator, enalapril, did not (5.971.2 to 6.271.1 mg/dl). 12 The uricosuric effect seen in treatment with losartan was not observed with enalapril in that study.
Owing to the lack of controlled intervention studies, SUA has been established as an independent risk factor for cardiovascular disease only via statistical adjustment; an association is well accepted, but causality is not. Puig et al. 13 and Ruilope et al. 14 failed to identify that losartan could significantly decrease the serum urate concentrations in hypertensive patients with elevated levels of SUA and hypertensive patients in their previous studies, respectively. The small sample size of patients evaluated in those studies may partly be responsible for the inconsistent results. Puig reported that losartan exerts a mild uricosuric effect in hypertensive patients (25%), but over 4 weeks did not produce a significant decline in serum urate. 13 In the present study, confounding variables that may influence uric acid levels, such as race, diet, drugs, exercise, renal insufficiency, were considered as exclusion criteria at baseline. In this study, losartan treatment induced a significant decrease in SUA levels in Chinese patients with hypertension and high levels of uric acid, which is in agreement with the results reported by several others, 2, 9, 11, 12 irbesartan had no significant effect on SUA.
Since serum urate is elevated in renal dysfunction or inappropriate diet and may be a marker for cardiovascular disease and a thiazide is often coprescribed with an angiotensin receptor blocker, the uricosuric effect of losartan may be useful to counteract any rise in urate or increase in risk of gout. Losartan has no indication for the treatment of elevated levels of SUA, but is indicated for the treatment of hypertension. Several studies have indicated that increased SUA might be an independent risk factor for hypertension-associated morbidity and mortality, so losartan may be a good option in hypertensive patients with elevated levels of SUA.
Limitations
It may be worth pointing out that the uricosuric effect of losartan might be particularly useful in patients with renal dysfunction and those on diuretics (for hypertension and heart failure). However, the primary aims of this study were to compare the effects of losartan and irbesartan on the SUA levels and the antihypertensive efficacy in Chinese patients with mild to moderate essential hypertension and high levels of SUA. The patients complicating with other diseases such as heart failure, acute myocardial infarction, etc., need to take the other drugs (diuretic, b-blocker, etc.) which will affect the level of SUA or blood pressure. If these patients were enrolled into this study, they should stop to take the drugs (diuretic, b-blocker, etc.), which would lead to the clinical conditions worsen. So these patients that were known to benefit from angiotensin receptor blockers were excluded in this study. The subjects enrolled in this study just had mild to moderate hypertension, in whom monotherapy should be effective. This is the limitation of this study.
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